The FDA has approved Juvmo (tavapadon), a once-daily pill for Parkinson’s disease rooted in decades of UVA Health research by Richard Mailman and Xuemei Huang. Unlike levodopa, this first-in-class D1 agonist selectively activates dopamine receptors, potentially offering fewer side effects and longer-lasting symptom relief for the 11 million people worldwide living with Parkinson’s.
The National Security Commission on Emerging Biotechnology visited UVA for a day exploring the university’s work in biotechnology, AI, data science, and research security. Led by alumna Caitlin Frazer, the visit included tours, student discussions, and sessions highlighting UVA’s role in advancing national security priorities and innovation.
On August 4, 2026, the UVA Paul and Diane Manning Institute of Biotechnology hosted its inaugural SPARK Tank competition, bringing together a dynamic mix of faculty, including from the School of […]
GET THE STORIES BEHIND THE RESEARCH
Receive updates about the discoveries, researchers, and ideas shaping our world — straight from UVA.